|
The SARS-CoV-2 spike (S) glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes.1 Multiple SARS-CoV-2 mutations in the S glycoprotein are currently under study, in particular three mutations in the receptor binding domain (RBD), K417N, E484K and N501Y, that may have functional significance.2 Structural modeling and mouse studies indicate N501Y increases S glycoprotein binding to ACE2, resulting in increased SARS-CoV-2 virulence.3,4 In addition, the E484K mutation drives immune evasion by altering RBD conformation and has been identified in escape mutants for convalescent antisera.5
The SARS-CoV-2 S glycoprotein is a key target for vaccine development efforts, as well as diagnostic and surveillance measures. To support these efforts, recombinant forms of the S glycoprotein and RBD from SARS-CoV-2 variants of interest and concern are now available in the BEI Resources catalog. The purity, concentration and functional activity are detailed on the Certificates of Analysis. Please consult the product documentation located on the product web pages for specific information on each protein.
The SARS-CoV-2 S glycoproteins were contributed or manufactured by Dr. Florian Krammer and Fatima Amanat, Icahn School of Medicine at Mount Sinai, New York, New York, and Dr. Noah Sather, Center for Global Infectious Diseases, Seattle Children's Research Institute, Seattle, Washington.
|
BEI Resources
|
Product Description
|
|
NR-54004
|
Spike Glycoprotein RBD from SARS-CoV-2, United Kingdom Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells
|
|
NR-54005
|
Spike Glycoprotein RBD from SARS-CoV-2, South Africa Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells
|
|
NR-55307
|
Spike Glycoprotein (Stabilized) from SARS-CoV-2, P.1 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells
|
|
NR-55310
|
Spike Glycoprotein (Stabilized) from SARS-CoV-2, B.1.351 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells
|
|
NR-55311
|
Spike Glycoprotein (Stabilized) from SARS-CoV-2, B.1.1.7 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells
|
|
NR-55438
|
Spike Glycoprotein (Stabilized) from SARS-CoV-2, B.1.526 Lineage with C-Terminal Histidine and Avi Tags, Recombinant from HEK293 Cells
|
References:
- Hulswit, R. J. G., C. A. M. de Haan and B.-J. Bosch. “Coronavirus Spike Protein and Tropism Changes.” Adv. Virus Res. 96 (2016): 29-57. PubMed: 27712627.
- Tegally, H., et al. “Emergence and Rapid Spread of a New Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Lineage with Multiple Spike Mutations in South Africa.” medRxiv (2020). doi:10.1101/2020.12.21.20248640.
- Gu, H., et al. “Adaptation of SARS-CoV-2 in BALB/c Mice for Testing Vaccine Efficacy.” Science 369 (2020): 1603-1607. PubMed: 32732280.
- Leung, K., et al. “Early Transmissibility Assessment of the N501Y Mutant Strains of SARS-CoV-2 in the United Kingdom, October to November 2020.” Euro. Surveill. 26 (2021): 2002106. PubMed: 33413740.
- Andreano, E., et al. “SARS-CoV-2 Escape in vitro from a Highly Neutralizing COVID-19 Convalescent Plasma.” bioRxiv (2020): 10.1101/2020.12.28.424451. PubMed: 33398278.
Image: Transmission electron micrograph of a SARS-CoV-2 virus particle (NIAID/CC BY 2.0)
|